Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
NASDAQ 4,148.34 21.37 0.52%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,391.58 -13.41 -0.09%
TOPIX 1,167.65 2.75 0.24%
HANG SENG 22,562.80 53.16 0.24%

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Dynavax Technologies



  Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of
  $100,000 Investing In Dynavax Technologies Corporation To Contact The Firm

PR Newswire

NEW YORK, June 21, 2013

NEW YORK, June 21, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading
national securities law firm, is investigating potential securities fraud at
Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX).

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

The investigation focuses on whether Dynavax made materially false and
misleading statements regarding the viability of HEPLISAV, the Company's lead
product candidate.  Specifically, the investigation focuses on whether Dynavax
failed to disclose: (i) that the clinical trial for HEPLISAV was flawed in
that it was not representative of the United States population and did not
provide information regarding concurrent use of HEPLISAV with other vaccines;
and (ii) the Company did not provide the Food and Drug Administration ("FDA")
with adequate information regarding HEPLISAV manufacturing processes and
controls.

On June 10, 2013, Dynavax issued a press release announcing that the FDA would
require additional safety trials prior to granting approval of HEPLISAV. 
Following this news, Dynavax's stock price dropped $1.07 or 43%. 

Request more information now by clicking here:  www.faruqilaw.com/DVAX.  There
is no cost or obligation to you.

Take Action
If you invested in Dynavax stock or options between April 26, 2012 and June
10, 2013 and would like to discuss your legal rights, visit
www.faruqilaw.com/DVAX.  You can also contact us by calling Richard Gonnello
or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by
sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. 
Faruqi & Faruqi, LLP also encourages anyone with information regarding
Dynavax's conduct to contact the firm, including whistleblowers, former
employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or
predict a similar outcome with respect to any future matter.  We welcome the
opportunity to discuss your particular case.  All communications will be
treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

 

SOURCE Faruqi & Faruqi, LLP

Website: http://www.faruqilaw.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement